重组人生长激素治疗幼年皮肌炎合并糖皮质激素相关生长障碍儿童的疗效与安全性
该回顾性队列纳入16例难治性幼年皮肌炎合并糖皮质激素相关生长障碍患儿,给予重组人生长激素0.10-0.15 IU/kg/天治疗6-24个月。治疗6个月后身高Z评分和生长速度显著改善,仅1例(6.25%)复发,未观察到代谢或内分泌不良事件;作者认为可考虑作为潜在治疗选择,但需进一步大规模多中心研究证实。
要点
- 治疗6个月后身高Z评分由-2.37±1.15升至-1.73±1.06(P<0.001)。
- 生长速度由2.74±1.53 cm/年增至13.05±3.64 cm/年(P<0.001)。
- 仅1例(1/16,6.25%)复发,未观察到代谢或内分泌不良事件。
核心结论
- 在合并生长障碍的幼年皮肌炎患者中,重组人生长激素治疗可考虑作为潜在治疗选择,依据为初步证据。
- 本研究提示其安全性可接受,且对改善生长参数有潜在疗效,即使在难治性病例中亦然。
- 需进一步开展更大规模的多中心研究以确认其在幼年皮肌炎中的应用价值。
研究设计与样本
- 回顾性队列研究,纳入16例接受重组人生长激素(0.10-0.15 IU/kg/天)治疗6-24个月的难治性幼年皮肌炎患者。
- 记录并分析身高Z评分、生长速度、生化标志物、疾病活动度和不良事件等结局。
主要发现
- 重组人生长激素治疗6个月后,身高Z评分由基线-2.37±1.15改善至-1.73±1.06(P<0.001)。
- 生长速度由2.74±1.53 cm/年增至13.05±3.64 cm/年(P<0.001)。
- 血清胰岛素样生长因子1由264.13±81.24 ng/ml升至351.59±123.41 ng/ml,碱性磷酸酶由242.40±42.25 U/l升至318.70±86.12 U/l(P<0.05)。
- 肌酸激酶由79.33±27.56 U/l升至111.60±42.84 U/l(P<0.01),但仍处于正常范围内。
- 仅1例患者(1/16,6.25%)出现幼年皮肌炎复发,低于未接受重组人生长激素治疗的幼年皮肌炎患者报告的复发率(31.6%);未观察到代谢或内分泌不良事件。
临床怎么用
- 作者认为,对合并生长障碍的幼年皮肌炎患者,重组人生长激素治疗可考虑作为潜在治疗选择,依据为初步证据。
- 作者指出,需进一步开展更大规模的多中心研究以确认重组人生长激素在幼年皮肌炎中的应用价值。
局限性
- 本研究为回顾性队列研究。
- 本研究样本量为16例。
- 需进一步开展更大规模的多中心研究以确认重组人生长激素在幼年皮肌炎中的应用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of recombinant human growth hormone (rhGH) in children with JDM experiencing glucocorticoid (GC)-induced growth failure. METHODS: A retrospective cohort study included 16 refractory JDM patients treated with rhGH (0.10-0.15 IU/kg/day) for 6-24 months. Outcomes including height Z-score, growth velocity (GV), biochemical markers, disease activity and adverse events were recorded and analysed. RESULTS: After 6 months of rhGH treatment, the height Z-score improved from -2.37 ± 1.15 at baseline to -1.73 ± 1.06 (P < 0.001), and GV increased from 2.74 ± 1.53 cm/year to 13.05 ± 3.64 cm/year (P < 0.001). Serum insulin-like growth factor 1 and alkaline phosphatase levels rose significantly (from 264.13 ± 81.24-351.59 ± 123.41 ng/ml and 242.40 ± 42.25-318.70 ± 86.12 U/l, respectively; P < 0.05). Creatine kinase levels increased but remained within the normal range (from 79.33 ± 27.56-111.60 ± 42.84 U/l; P < 0.01). Only one patient (1/16, 6.25%) experienced JDM relapse, a rate lower than the reported recurrence rate (31.6%) in JDM patients not receiving rhGH treatment. No adverse metabolic or endocrine effects were observed. CONCLUSION: In JDM patients with growth failure, rhGH therapy may be considered as a potential treatment option, supported by preliminary evidence. Our study suggests an acceptable safety profile and potential efficacy in improving growth parameters, even in refractory cases. Further larger-scale multicentre studies will be necessary to confirm its application value in JDM.
引用
- Wang X, Wang X, Huang B, et al. Efficacy and safety of rhGH in juvenile dermatomyositis children with glucocorticoid-related growth failure. Rheumatology (Oxford). 2025. PMID: 40577072. doi:10.1093/rheumatology/keaf236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。